BridgeBio Oncology’s Marc Cobo sells 78 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics, Inc. (BBOT) Principal Accounting Officer Marc Cobo sold 78 shares of common stock at $2.37 per share on November 13, 2026, under a Rule 10b5-1 sales plan adopted July 24, 2026. He held 13,734 shares directly after the sale.
Insider Trade Summary 10b5-1
Net Seller: 78 shares
Net Sell
1 txn
Insider
Cobo Marc
Role
Principal Accounting Officer
Sold
78 shs ($184.86)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 78 | $2.37 | $184.86 |
Holdings After Transaction:
Common Stock — 13,734 shares (Direct)
Footnotes (1)
- F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 24, 2026.
Key Figures
Shares sold: 78 shares
Sale price: $2.37 per share
Direct shares held after sale: 13,734 shares
3 metrics
Shares sold
78 shares
Common stock sold on November 13, 2026
Sale price
$2.37 per share
Common stock sale on November 13, 2026
Direct shares held after sale
13,734 shares
Marc Cobo's reported direct holdings following the November 13, 2026 sale
Key Terms
Rule 10b5-1 sales plan
1 terms
Rule 10b5-1 sales plan regulatory
"sale effected pursuant to a Rule 10b5-1 sales plan"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.